Table 1.
Association of lncRNA‐HEIH up‐regulation with clinicopathologic features in ESCCs
| Clinical features | Number | lncRNA‐HEIH up‐regulation | P |
|---|---|---|---|
| Age, years | |||
| ≤60 | 53 | 40 (74.5%) | .926 |
| >60 | 38 | 29 (76.3%) | |
| Gender | |||
| Male | 49 | 35 (71.4%) | .290 |
| Female | 42 | 34 (81.0%) | |
| Differentiation | |||
| Well | 18 | 12 (66.7%) | .614 |
| Moderate | 46 | 36 (78.3%) | |
| Poor | 27 | 21 (77.8%) | |
| Tumour invasion | |||
| T1 | 5 | 1 (20.0%) | .017 a |
| T2 | 12 | 5 (41.7%) | |
| T3 | 37 | 24 (64.9%) | |
| T4 | 37 | 29 (78.4%) | |
| Lymph node metastasis | |||
| N0 | 56 | 36 (64.3%) | .001 a |
| N1 | 35 | 33 (94.3%) | |
| Clinical stage | |||
| Early (I‐II) | 60 | 39 (65%) | .001 a |
| Advanced (III‐IV) | 31 | 30 (96.8%) | |
a
Statistical significance (P < .05) is shown.